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Abstract: We aimed to identify a simple metric accounting for peri-procedural hemoglobin changes,
independent of blood product transfusion strategies, and assess its correlation with outcomes in
patients undergoing left ventricular assist device (LVAD) implantation We included consecutive
patients undergoing LVAD implantation at a single center between 10/1/2008 and 6/1/2014. The
anemia stress index (ASI), defined as the sum of number of packed red blood cells transfused and
the hemoglobin changes after LVAD implantation, was calculated for each patient at 24 h, discharge,
and 3 months after LVAD implantation. Our cohort included 166 patients (80.1% males, mean age
56.3 ± 15.6 years) followed up for a median of 12.3 months. Increases in ASI per unit were associated
with a higher hazard for all-cause mortality and early RV failure. The associations between the
ASI and all-cause mortality persisted after multivariable adjustment, irrespective of when it was
calculated (adjusted HR of 1.11, 95% CI 1.03–1.20 per unit increase in ASI). Similarly, ASI at 24 h
after implant was associated with early RV failure despite multivariable adjustment (OR 1.09, 95% CI
1.05–1.14). We present a novel metric, the ASI, that is correlated with an increased risk for all-cause
mortality and early RV failure in LVAD recipients.
Keywords: outcomes; left ventricular assist device

This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).

1. Introduction
Anemia is widely prevalent among patients with end-stage heart failure [1,2]. In
patients undergoing left ventricular assist device (LVAD) implantation, anemia is further
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worsened by surgical blood loss, coagulopathy, device-related hemolysis, a generalized
pro-inflammatory state, and the requirement for systemic anticoagulation [3]. Despite its
high prevalence, the impact of anemia in LVAD patients remains poorly characterized with
conflicting data on its association with morbidity and mortality [4–6].
As a consequence of peri-operative anemia at the time of LVAD implantation, blood
transfusions are very common in this period. Although transfusion rapidly corrects anemia,
studies assessing the impact of blood transfusions in patients undergoing cardiac surgery
suggest a number of potential adverse effects, mediated both by volume and cytokines,
resulting in the creation of a pro-inflammatory milieu, and the activation of leucocytes and
coagulation factors, with an exacerbation of oxidative stress [7,8]. Accordingly, assessing
the impact of anemia on outcomes in patients after LVAD implantation may be affected by
transfusion strategies.
In this study, we assessed the impact of pre-implant anemia and changes in hemoglobin
levels on outcomes of patients undergoing LVAD implantation, regardless of the transfusion strategy used. More specifically, we utilized a novel metric, the anemia stress index
(ASI), defined as the sum of the number of packed red blood cells transfused and difference
in hemoglobin levels pre- and post-LVAD implantation, and assessed its association with
all-cause mortality and early right ventricular failure after LVAD implantation. The ASI
assesses the actual change in hemoglobin after LVAD implantation and is not biased by
transfusion strategies that frequently vary by physician. We hypothesized that the ASI
calculated at different time points post-implant (at 24 h, on discharge, and at 3 months)
would be predictive of all-cause mortality.
2. Methods
2.1. Study Population and Data Collection
This was a retrospective cohort study involving a single, large, tertiary care academic
center. We included all consecutive patients who underwent continuous flow LVAD
implantation at the Hospital of the University of Pennsylvania between 1 October 2008
and 1 June 2014 and survived for at least 24 h after the surgery, with data available on preand post-LVAD implant hemoglobin levels and the number of transfusions. All charts for
inpatient hospitalization and outpatient visits were reviewed in detail by trained abstractors.
Demographic, clinical, laboratory, peri-procedural, and imaging data were collected in
detail via intensive chart review. The Institutional Review Board of the University of
Pennsylvania approved the study protocol.
2.2. Independent Variable
We abstracted pre-implant hemoglobin, defined as the hemoglobin value available
immediately prior to LVAD implantation. In addition, we collected the hemoglobin level at
various time points after LVAD implantation—at 24 h, discharge, and at 3 months. Detailed
data on the use of packed red blood cells (RBCs) during index hospitalization involving
the LVAD implant were collected.
Using these collected variables, we calculated the anemia stress index (ASI; Figure 1),
defined as:
Anemia stress index = pre-implant hemoglobin post-implant hemoglobin + number of packed RBCs transfused
The rationale for utilizing the ASI is that it takes into account the actual change in
hemoglobin occurring after LVAD implantation and is not biased by transfusion strategies,
which frequently vary by physician. In other words, it allows for objective assessment of
the change in hemoglobin following implantation which is not related to number of blood
transfusions given during the implant (i.e., assessment of the amount of bleeding on one
hand, and the ability to generate hemoglobin on the other hand). For example, if patient A
had a pre-implant hemoglobin level of 12 g/dL, and after receiving 3 U of PRBC in the perioperative period the post-implant hemoglobin at 3 months was 9 g/dL, the ASI value for
this patient is 6. If patient B had a pre-implant hemoglobin of 8 g/dL, received 3 U PRBC in
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the peri-operative period, and had a post-implant hemoglobin of 9 g/dL, the anemia stress
index value is 2. Although the amount of blood transfused for both these patients would
be the same due to variable practice patterns, and the post-implant hemoglobin levels were
J. Clin. Med. 2022, 11, x FOR PEER REVIEW
3 of 10
the same as well, the ASI values are different and reflect the changes in hemoglobin levels
in both patients.
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for the cohort), because extremes may bias generated estimates. The same analysis was
repeated using the ASI at discharge and ASI at 3 months post-discharge. The proportional
hazards assumption was evaluated and found to be met. In all analyses, participants were
censored if the participant was lost to follow-up, underwent a cardiac transplant, had a
device explant due to myocardial recovery, or reached the end of the follow-up period
(1 December 2017).
To assess the association between the ASI at 24 h after implant and early right ventricular (RV) failure after LVAD implantation, a logistic regression model was fitted with the
same covariates listed above.
All analyses were performed using STATA Statistical Software 11.2 (StataCorp, College
Station, TX, USA). All reported p values are two sided, and a p value of <0.05 was considered
statistically significant.
3. Results
Our study cohort comprised 166 patients who underwent LVAD implantation between 1 October 2008 and 1 June 2014. There were 133 (80.1%) males with a mean age of
56.3 ± 15.6 years. This included 78 (47%) patients with ischemic cardiomyopathy and
88 (53%) patients with non-ischemic, dilated cardiomyopathy. A HeartMate II device
was implanted in 140 patients (84.3%), and the remaining 26 patients (15.7%) received a
HeartWare LVAD. The implant strategy included 64 patients (38.6%) as bridge to transplant,
81 patients (48.8%) as destination therapy, 16 patients (9.6%) as bridge to decision, and
5 patients (3.0%) as bridge to recovery. Comorbidities were common, with diabetes prevalent in 45.2% and hypertension in 59.0% of the patients. The baseline median hemoglobin
level was 11.1 (IQR9.7–12.3) g/dL. Baseline characteristics of the cohort stratified into
quartiles by the ASI at 24 h after LVAD implantation are presented in Table 1.
Table 1. Baseline characteristics of the cohort stratified by the ASI at 24 h after LVAD implantation.
Quartile 1
ASI < 2
(n = 40)

Quartile 2
ASI > 2 to <5
(n = 40)

Quartile 3
ASI > 5 to <12
(n = 40)

Quartile 4
ASI > 12
(n = 46)

p Value

51.7 ± 14.9

52.5 ± 17.9

61.1 ± 15.4

59.6 ± 12.6

<0.01

28 (70%)

30 (75%)

32 (80%)

43 (93.5%)

0.04

Caucasian

17 (42.5%)

16 (40%)

15 (37.5%)

29 (63%)

African-American

6 (15.1%)

10 (25%)

6 (15%)

9 (19.6%)

Characteristic
Age, years
Male sex
Race

Other

0.26

3 (7.5)

1 (2.5%)

1 (2.5%)

0 (0)

14 (35%)

13 (32.5%)

18 (45%)

8 (17.4%)

BMI (mean ± SD)

30.5 ± 7.4

27.3 ± 6.1

27.7 ± 7.3

28.6 ± 5.4

0.13

Diabetes

19 (47.5%)

16 (40%)

18 (45%)

22 (47.8%)

0.88

Hypertension

25 (62.5%)

15 (37.5%)

23 (57.5%)

35 (76.1%)

<0.01
0.97

Unknown

Dyslipidemia

26 (65%)

25 (62.5%)

27 (67.5%)

30 (65.2%)

13 (32.5%)

14 (35%)

18 (45%)

23 (50%)

0.31

Stroke/TIA

8 (20%)

3 (7.5%)

4 (10%)

8 (17.4%)

0.31

Chronic renal disease

10 (25%)

15 (37.5%)

13 (32.5%)

20 (43.5%)

0.30

Prior CT surgery

10 (25%)

10 (25.0%)

18 (45%)

18 (39.1%)

0.13

17 (42.5%)

16 (40%)

19 (47.5%)

26 (56.5%)

18
0
2
1
0
0
1
1

19
1
0
2
1
0
1
0

16
0
0
1
0
1
2
1

17
0
0
0
0
1
1
1

Atrial fibrillation

HF etiology
Ischemic cardiomyopathy
Non ischemic cardiomyopathy:
-Idiopathic
-Congenital heart disease
-Viral cardiomyopathy
-Peripartum cardiomyopathy
-Alcohol-induced cardiomyopathy
-Myocarditis
-Chemotherapy-induced cardiomyopathy
-Valvular cardiomyopathy

0.60
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Table 1. Cont.
Quartile 1
ASI < 2
(n = 40)

Quartile 2
ASI > 2 to <5
(n = 40)

Quartile 3
ASI > 5 to <12
(n = 40)

Quartile 4
ASI > 12
(n = 46)

p Value

21 (52.5%)
14 (35%)
4 (10%)
0 (0)
1 (2.5%)

17 (43.6%)
14 (35.9%)
7 (17.9%)
1 (2.6%)
0 (0)

19 (47.5%)
15 (37.5%)
5 (12.5%)
1 (2.5%)
0 (0)

22 (50%)
14 (31.8%)
7 (15.9%)
1 (2.3%)
0 (0)

0.93

23 (57.5%)

13 (32.5%)

11 (27.5%)

17 (36.9%)

6 (15%)

2 (5%)

4 (10%)

4 (8.7)

11 (27.5%)

21 (52.5%)

24 (60%)

25 (54.3%)

0 (0)

4 (10%)

1 (2.5%)

0 (0)

HeartMate II

30 (75%)

36 (90%)

34 (85%)

40 (86.9%)

HeartWare

10 (25%)

4 (10%)

6 (15%)

6 (13%)

Pulmonary hypertension

13 (32.5%)

16 (40%)

16 (40%)

11 (24.4%)

0.37

COPD

9 (23.1%)

3 (7.5%)

8 (20%)

9 (19.6%)

0.27

History of smoking

16 (40%)

17 (42.5%)

16 (40%)

19 (41.3%)

0.99

11.2 (8.9–12.3)

11.4 (10.0–12.9)

11.1 (10.2–12.2)

10.6 (9.4–12.0)

0.18

194.6 ± 79.6

178.3 ± 58.2

191.3 ± 64.2

192.4 ±75.1

0.72

3.4 ± 0.6

3.4 ± 0.5

3.4 ± 0.5

3.3 ± 0.7

0.71

Characteristic
LVAD reason
Cardiogenic shock
Inotrope-dependent heart failure
Worsening, non-inotrope-dependent heart failure
Intractable ventricular arrhythmia
Pump exchange
LVAD indication
Bridge to transplant
Bridge to decision
Destination therapy
Bridge to recovery

0.01

LVAD type

Hemoglobin baseline (median, IQR)
Platelet baseline (mean ± SD)
Albumin (mean ± SD)

0.28

BMI—body mass index; COPD—chronic obstructive pulmonary disease; CT—cardiothoracic; IQR—interquartile
range; LVAD—left ventricular assist device; SD—standard deviation; TIA—transient ischemic attack.

3.1. Association between the ASI at 24 h after LVAD Implant and All-Cause Mortality
The median follow-up duration was 12.3 months (IQR 3.4—37.6); there were 86 deaths
6 of 10
patients) during this period. In the unadjusted analysis, we observed
a statistically
significant relationship between the ASI at 24 h post-LVAD implant and all-cause mortality
(HR 1.05; 95% CI 1.03—1.07, p < 0.01; Figure 2). After multivariable adjustment, the
mortality (HR 1.05; 95% CI 1.03—1.07, p < 0.01; Figure 2). After multivariable adjustment,
association
between the ASI and all-cause mortality over the follow-up period persisted,
the association between the ASI and all-cause mortality over the follow-up period perwith
an
adjusted
HRHRofof1.08
(95%CICI
1.03—1.14,
p <Table
0.01;
2). Other variables that
sisted, with an adjusted
1.08 (95%
1.03—1.14,
p < 0.01;
2).Table
Other variables
correlated
with
mortality
included
in Supplemental
that correlated
withtime
time to
to mortality
areare
included
in Supplemental
Table S1. Table S1.
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Figure 2. Kaplan–Meier survival estimates of the cohort stratified by quartiles of the anemia stress

Figure
survival estimates of the cohort stratified by quartiles of the anemia stress
index at 2.
24 Kaplan–Meier
h post-LVAD implantation.
index at 24 h post-LVAD implantation.
Table 2. Results of the Cox proportional hazards model exploring the association between the ASI
and all-cause mortality.

Unadjusted HR (95% CI) for MortalAdjusted HR (95% CI) for Mortality
ity
Anemia stress index at 24 h post-im-

1.09 (1.04–1.14)

1.08 (1.03–1.14)
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Table 2. Results of the Cox proportional hazards model exploring the association between the ASI
and all-cause mortality.
Unadjusted HR (95% CI) for Mortality

Adjusted HR (95% CI) for Mortality

Anemia stress index at 24 h post-implant

1.09 (1.04–1.14)

1.08 (1.03–1.14)

Anemia stress index at discharge

1.04 (1.01–1.07)

1.08 (1.00–1.16)

Anemia stress index at 3 months after
LVAD implant

1.05 (1.02–1.07)

1.09 (1.02–1.16)

3.2. Association between the ASI at 24 h after LVAD Implant and Early Right Ventricular Failure
Early RV failure after LVAD implantation was seen in 32 (19.3%) patients. In the
unadjusted model, there was a significant association between the ASI at 24 h post-implant
and early RV failure post-LVAD implantation during the index hospitalization (OR 1.08;
95% CI 1.04–1.12; p < 0.01). Following multivariable adjustment, this association remained
statistically significant (OR 1.09, 95% CI 1.04–1.14; p < 0.01; Table 3).
Table 3. Results of the multivariable model exploring the association between the ASI at 24 h
post-LVAD implant and early right ventricular failure after LVAD implantation.
Characteristic

OR (95% CI)

p Value

Anemia stress index * at 24 h

1.09 (1.04–1.14)

<0.01

Age *

0.99 (0.95–1.03)

0.53

Male sex

1.25 (0.37–4.24)

0.72

BMI *

0.99 (0.91–1.06)

0.73

Diabetes

1.07 (0.42–2.74)

0.89

COPD

2.30 (0.74–7.21)

0.74

Pulmonary hypertension

1.06 (0.40–2.80)

0.40

Smoking history

0.62 (0.24–1.64)

0.34

Atrial fibrillation

1.35 (0.51–3.57)

0.55

Chronic renal disease

1.50 (0.55–4.10)

0.55

Prior CT surgery

1.01 (0.39–2.64)

0.98

LVAD indication **
Bridge to transplant

Reference

Bridge to decision

1.06 (0.22–5.16)

0.94

Destination therapy

0.76 (0.26–2.23)

0.62

BMI—body mass index; COPD—chronic obstructive pulmonary disease; CT—cardiothoracic; LVAD—left ventricular assist device. * Treated as a continuous variable; ** Stratified into bridge to transplant, bridge to recovery,
bridge to decision, and destination therapy.

3.3. Association between the ASI at Discharge and All-Cause Mortality
At total of 139 (83.7%) patients survived the index hospitalization after LVAD implantation. In the unadjusted analysis, we observed a statistically significant relationship
between the ASI at discharge and mortality (HR 1.04, 95% CI 1.01–1.07; p < 0.01). After
multivariable adjustment, the association between the ASI and mortality over the follow-up
period persisted, with an adjusted HR of 1.08 (95% CI 1.00–1.16, p = 0.04; Table 2).
3.4. Association between the ASI at 3 Months after LVAD Implant and All-Cause Mortality
A total of 128 (77.1%) patients survived longer than 3 months after LVAD implantation.
In the unadjusted analysis, we observed a statistically significant relationship between
the ASI at 3 months and all-cause mortality (HR 1.05, 95% CI 1.02–1.07; p < 0.01). After
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multivariable adjustment, the association between the ASI and mortality over follow-up
persisted, with an adjusted HR of 1.09 (95% CI 1.02–1.16, p = 0.01; Table 2).
4. Discussion
We assessed the impact of a change in hemoglobin level regardless of the blood
transfusion strategy on all-cause mortality and early post-implant right ventricular failure.
We propose a novel and simple prognostic tool, called the “Anemia stress index”, which is
a composite of the difference in hemoglobin prior to and after LVAD implantation and the
number of packed red blood cells transfused. In our study, the ASI was correlated with
all-cause mortality and early RV failure after LVAD implantation. This association persisted
after multivariable adjustment for clinically significant confounders. Furthermore, the ASI
was correlated with post-LVAD implant survival at all evaluated time points.
4.1. Prior Studies
Traditionally, anemia has been shown to be an independent marker of morbidity
and all-cause mortality among patients with HF, with several studies showing a linear
correlation between hemoglobin and mortality risk [2,11]. The pathogenesis of anemia
in HF is multifactorial, and existing evidence suggests that it maybe secondary to renal
dysfunction [12], with neurohormonal [13,14] and proinflammatory cytokine activation and
bone marrow hypo-responsiveness [15]. The vast majority of HF patients also have some
degree of iron deficiency [16]. Some studies suggest that LVADs may help to reverse the
neurohormonal activation seen in HF; however, the prevalence of anemia among patients
with LVADs remains high and has been reported to range from 46% to 80% in single-center
cohorts [5,6,17,18].
Among factors contributing to the progression of anemia after LVAD implantation,
peri-operative bleeding plays a major role, in addition to ongoing inflammation, hemolysis,
and gastrointestinal bleeding [5]. Although blood transfusions provide a rapid, short-term
solution to anemia, observational studies suggest an association between transfusions
and increased rates of infection, ischemic complications, RV failure, and death in patients
undergoing coronary artery bypass grafting [7,8]. Our previous study showed a positive
correlation between blood transfusions and one-year mortality in LVAD patients [6,19,20].
Furthermore, practice patterns with regard to transfusion thresholds vary significantly
across providers. Accordingly, assessing the degree of anemia in patients with LVADs must
include an estimation of the amount of blood products received.
4.2. Study Implications
Our study highlights the importance of calculating ASI values for every LVAD patient as an additional prognostic factor, irrespective of the different transfusion strategies
employed. It is a simple and easy tool which can be readily used to risk-stratify patients
after LVAD implantation. It correlated with all-cause mortality irrespective, of the time
after LVAD implantation when it was calculated. Future randomized studies are needed to
evaluate strategies of decreasing the ASI score by increasing the post-implant hemoglobin
levels, such as by treating LVAD candidates with intravenous iron therapy. Our novel ASI
score enables estimation of the blood loss and hemoglobin generation, regardless of the
transfusion strategy.
4.3. Study Limitations
The results of our study should be interpreted in the light of several potential limitations. First, we did not have information regarding the etiology of anemia. However, our
study has shown that ASI is an effective prognostic tool and reflects real-world practice
and outcomes. Second, our study was observational in nature and we cannot establish
causality, and the possibility of residual confounding exists. For example, we do not have
more granular data on peri-operative details such as cross clamp time; nonetheless, we
utilized a large number of covariates that influence outcomes after LVAD implantation, and
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this has likely reduced this source of error. Third, we do not have longer-term follow-up
data available on our cohort to provide data on longer-term outcomes.
5. Conclusions
In conclusion, assessing the impact of anemia on the outcomes of LVAD patients is
limited by blood product transfusion strategies which are frequently not standardized. We
present a novel metric comprising the sum of the difference in hemoglobin levels prior to
and after LVAD implantation with amount of packed RBC transfused (anemia stress index),
which correlated with both all-cause mortality and early right ventricular failure after
LVAD implantation. Accordingly, using the anemia stress index can help to risk-stratify
patients after LVAD implantation. Additional studies are needed to explore therapeutic
strategies which will result in a lower anemia stress index in an effort to improve outcomes
for patients on durable LVAD support.
Supplementary Materials: The following supporting information can be downloaded at: https://
www.mdpi.com/article/10.3390/jcm11154517/s1, Table S1: Results of Cox Regression model examining
association between ASI at 24 h post LVAD implant and time to mortality. * estimate not calculated due
to very small number of patients.
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